Advanced searches left 3/3

Cardiovascular - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 22 August 2022

* If you want to update the article please login/register

Sleep Duration and Cardiovascular Health

In short sleepers and long sleepers, it is difficult to test the possibility that vascular endothelial function in the brachial artery and other related cardiovascular risk markers are impaired in comparison to the control group of average duration sleepers. OUTLINE: Participants will monitor sleep, physical activity, and blood pressure with at-home computers before coming in for one in-lab visit, where they will be able to measure calcium in the coronary arteries, as well as an optional CT scan to determine calcium in the coronary arteries.

Source link: https://clinicaltrials.gov/ct2/show/NCT04804124


Cardiovascular Evaluation of Homozygous Familial Hypercholesterolemia

Liver transplantation has been shown to virtually normalize plasma lipoprotein concentrations in homozygous FH, and the recent cloning of a functional LDL receptor gene has paved the way for definitive therapy of this disease. These patients' Sequential cardiovascular research will not only document the progression of atherosclerosis heart disease in this disease, but it will also enable the identification of individuals with whom would be able to benefit from liver transplantation and/or genetic engineering.

Source link: https://clinicaltrials.gov/ct2/show/NCT00001204


Technical Development of Cardiovascular MRI

Aims: To determine the success of novel pulse sequences for cardiovascular MRI in patients and healthy volunteers. Primary Endpoint : Endpoints: Primary Endpoint : The number of subjects with custom and novel pulse sequences that have contributed to diagnostic quality images is a measure of clinical success.

Source link: https://clinicaltrials.gov/ct2/show/NCT04927429


Resveratrol and Cardiovascular Health in the Elderly: The Reache Trial

Resveratrol is present in grape leaves and skin, in peanuts, and in the plant polygonum cupsidatum's roots. Resveratrol may have some of the same effects as reduced food intake, perhaps through its action on a protein in the body called Sirtuin, which is important because it is one of the few approaches that have consistently demonstrated positive effects on the aging process. A new NIA-conducted monkey study in monkeys revealed a decrease in the stiffness of blood vessels over several weeks, which was included in the monkey studies. Healthy human volunteers or in patients with type II diabetes mellitus have begun to identify potential uses for resveratrol as a dietary supplement, and the drug appears to have no adverse effects at doses up to 5 grams per day. To prevent neurodegenerative diseases such as Alzheimer's disease, there has also been increasing interest in pharmacological interventions targeting cardiovascular risk factors such as atherosclerosis and type II diabetes. In 120 random overweight/obese people over the age of 50, we will conduct a 12-month trial of resVida. Participants 50 years or older will be self-administered twice a day for 52 weeks. The primary endpoint will be vascular stiffness, while the secondary endpoint will be exercise capacity as determined by oxygen usage. Testing will be carried out in the blood to determine the amount of resveratrol in the blood in different doses of the drug.

Source link: https://clinicaltrials.gov/ct2/show/NCT01842399


Cardiovascular Health and Needs Assessment in Washington D.C. - Development of a Community-Based Behavioral Weight Loss Intervention

Obesity has been correlated to an elevated risk of cardiovascular risk factors and cardiovascular disease. Many people who are at risk of obesity and obesity-related cardiovascular risk factors can be reached by community-based programs. Interventions based on community-based participatory research principles continue to develop in collaboration with community partners, enabling an intervention's elements to be tailored to the community's particular needs. Therefore, we recommend a cardiovascular health screening and needs evaluation of a sample population from predominantly African-American churches in Wards 5, 7, and 8. Based on the control of risk factors and lifestyle habits, cardiovascular health indicators can be classified as desirable, intermediate, or poor. We hypothesize that the percentage of the church-based population that meets recommended criteria for each of the cardiovascular health risk factors will be lower than that of the population that meets intermediate and poor cardiovascular health indicators.

Source link: https://clinicaltrials.gov/ct2/show/NCT01927783


Sleep Loss, Cardiovascular Physiology, and Social Experiences Study

African Americans aredisproportionately burdened by medical and subcutaneous cardiovascular disease among AAs, with elevated daytime and nighttime blood pressure contributing to CVD morbidity among AAs, but the exact mechanisms explaining these relationships are uncertain. However, evidence demonstrating racial discrimination and poor sleep is growing, but it is largely based on cross-sectional studies. In a separate study, the investigators are investigating the effects of perceived discrimination on sleep and nocturnal physiology. The investigators are also investigating whether experimental sleep loss influences one's appearance and reaction to social interaction tasks with an outgroup member of an outgroup group. The investigators will randomly assign 80 healthy AAs to one night of total sleep restriction or normal sleep in the sleep lab and then test them on a variety of common social experience tasks.

Source link: https://clinicaltrials.gov/ct2/show/NCT05166590


Reducing Cardiovascular Disease Risk in Perimenopausal Latinas: Pilot Study of a Multi-Component Intervention

Although CVD mortality is the leading cause of death in the United States, large racial/ethnic inequalities in cardiovascular health exist between Latinas and non-Hispanic populations. Following menopause, the risk of CVD rises for women. During perimenopause, CVD risk factors, including perimenopause, are on the rise in CVD risk factors, including systolic blood pressure, fasting glucose, total cholesterol, and systolic blood pressure, in comparison to premenopausal women. Although behavioral intervention research into CVD risk during perimenopause has increased over the past decade, no studies have been conducted to reduce biological CVD risk among perimenopausal Latinas. Health habits and self-efficacy, as well as other physical risk factors related to CVD risk will be included in the secondary findings, which will include lifestyle changes and self-efficacy, as well as other health risk factors. This paper has the potential to accelerate significantly the acquisition of information related to CVD risk among perimenopausal Latinas, as well as the effect of behavioral interventions to reduce CVD risk in this underserved population.

Source link: https://clinicaltrials.gov/ct2/show/NCT04313751


Cardiovascular Diagnostic in Assessment of Risk High Dose Chemotherapy and Hematopoietic Cell Transplantation in Patients With Haemoblasts.

Heart failure, arrhythmias, systolic and diastolic dysfunction, valvular disease, pericarditis, inflammatory heart disease, cardiomyopathy, stroke, and hypertension can be among the short- and long-term cardiotoxic effects associated with anticancer therapy. Autologous and allogeneic cell transplantation has been shown to an elevated incidence of cardiovascular disease and worsening of cardiovascular risk factors, which may lead to increased cardiovascular disease and cardiovascular risk factors in later CVD. These findings, as well as a notable rise in the number of survivors following HCT in recent years, highlight the need for research aimed at reducing risk or preventing these outcomes by changing specific strategies and/or post-HCT interventions. Patients with confirmed hemoblastosis were included in this study. Patients were refused by patients who were over 18 years old and preparing for high dose chemotherapy and hematopoietic cell transplantation, according to Exclusion criteria.

Source link: https://clinicaltrials.gov/ct2/show/NCT05508087

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions